Csea

Cidara Therapeutics, based in San Diego, CA, specializes in developing targeted immunotherapies aimed at enhancing patient outcomes for those facing serious diseases. The company's innovative Cloudbreak platform combines targeted small molecules and peptides with human antibody fragments to create drug-Fc conjugate (DFC) immunotherapies that engage the immune system and inhibit specific disease targets. With a commitment to improving the standard of care, Cidara Therapeutics focuses on transformative solutions in areas such as immuno-oncology and influenza. Their approach represents a significant advancement in the field of targeted immunotherapy, reflecting their mission to save lives through cutting-edge medical innovation. Generated from the website